John J. Sperzel III, B.Sc.
Net Worth
Last updated:
What is John J. Sperzel III, B.Sc. net worth?
The estimated net worth of Mr. John J. Sperzel III, B.Sc. is at least $2,698,206 as of 24 Feb 2024. He owns shares worth $217 as insider, has earned $6,179 from insider trading and has received compensation worth at least $2,691,810 in T2 Biosystems, Inc..
What is the salary of John J. Sperzel III, B.Sc.?
Mr. John J. Sperzel III, B.Sc. salary is $897,270 per year as Chairman & Chief Executive Officer in T2 Biosystems, Inc..
How old is John J. Sperzel III, B.Sc.?
Mr. John J. Sperzel III, B.Sc. is 62 years old, born in 1963.
What stocks does John J. Sperzel III, B.Sc. currently own?
As insider, Mr. John J. Sperzel III, B.Sc. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| T2 Biosystems, Inc. (TTOO) | Chairman & Chief Executive Officer | 17,329 | $0.01 | $217 |
What does T2 Biosystems, Inc. do?
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
John J. Sperzel III, B.Sc. insider trading
T2 Biosystems, Inc.
Mr. John J. Sperzel III, B.Sc. has made 2 insider trades between 2022-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 333,333 units of TTOO stock on 24 Feb 2022. As of 24 Feb 2024 he still owns at least 17,329 units of TTOO stock.
T2 Biosystems key executives
T2 Biosystems, Inc. executives and other stock owners filed with the SEC:
- Mr. Alec J. Barclay (45) Chief Operations Officer
- Mr. John J. Sperzel III, B.Sc. (62) Chairman & Chief Executive Officer